Saruhashi Y, Young W, Hassan A Z
Department of Neurosurgery, New York University Medical Center, NY 10016, USA.
Neuroscience. 1997 Dec;81(4):959-65. doi: 10.1016/s0306-4522(97)00219-4.
We carried out experiments to investigate the mechanisms of serotonin-induced axonal excitability changes using isolated dorsal columns from young (seven to 11-day-old) Long-Evan's hooded rats. Conducting action potentials were activated by submaximal (50%) and supramaximal constant current electrical stimuli and recorded with glass micropipette electrodes. In experiment 1, to study Ca(2+)-mediated mechanisms, we superfused the preparations with Ringer solutions containing varying Ca2+ concentrations. Following superfusion with Ca(2+)-free Ringer solution for 4 h, we tested initial responses to serotonin agonists. Studies then were repeated after preparations had been washed for 1 h with Ringer solution containing 1.5 mM Ca2+ and 1.5 mM Mg2+. After 4 h superfusion of Ca(2+)-free Ringer solution, quipazine (a serotonin2A agonist, 100 microM) did not induce significant axonal excitability changes (amplitude change of 1.4 +/- 1.3%, percentage of predrug control level, +/-S.D., n = 6). A 100 microM concentration of 8-hydroxy-dipropylaminotetralin (a serotonin1A agonist) reduced response amplitudes by 36.3 +/- 4.2% (+/-S.D., P < 0.0005, n = 7) and prolonged latencies by 22.3 +/- 4.3% (+/-S.D., P < 0.0005, n = 7). Application of serotonin (100 microM) decreased amplitudes by 6.6 +/- 5.0% (+/-S.D., P < 0.05, n = 6). Extracellular calcium concentration ([Ca2+]e) was measured at various depths in the dorsal column with ion-selective microelectrodes. Four hours' superfusion with Ca(2+)-free Ringer solution reduced [Ca2+]e to less than 0.1 mM in dorsal columns. In 1.5 mM Ca2+ Ringer solution, quipazine increased the amplitudes by 38.3 +/- 5.8% (P < 0.0005, n = 6). Likewise, serotonin increased the amplitudes by 13.8 +/- 4.9% (P < 0.005, n = 6). In contrast however, 8-hydroxy-dipropylaminotetralin still reduced amplitudes by 35.0 +/- 6.4% (P < 0.0005, n = 7) and prolonged latencies by 24.1 +/- 4.5% (P < 0.0005, n = 7). In experiment 2, we investigated calcium-dependent and cAMP-mediated protein kinase signalling pathways to evaluate their role as intracellular messengers for serotonin2A receptor activation. Two protein kinase inhibitors, 50 microM H7 (an inhibitor of protein kinase C and c-AMP dependent protein kinase) and 100 microM D-sphingosine (an inhibitor of protein kinase A and C) effectively eliminated the excitatory effects of the serotonin2A agonist. 100 microM cadmium (a Ca2+ channel blocker) also blocked the effects of quipazine. Neither these protein kinase inhibitors nor cadmium alone affected action potential amplitudes. These results suggest that replacing Ca2+ with Mg2+ blocks the excitatory effects of quipazine but does not prevent the inhibitory effects of 8-hydroxy-dipropylaminotetralin, and calcium-mediated protein kinase mechanisms modulate axonal excitability changes induced by serotonin and its agonist.
我们进行了实验,以研究5-羟色胺诱导轴突兴奋性变化的机制,实验采用来自幼年(7至11日龄)Long-Evan's有帽大鼠的分离背柱。传导动作电位由次最大(50%)和超最大恒定电流电刺激激活,并用玻璃微电极记录。在实验1中,为研究Ca(2+)介导的机制,我们用含不同Ca2+浓度的林格液灌注标本。在用无Ca(2+)林格液灌注4小时后,我们测试了对5-羟色胺激动剂的初始反应。然后在标本用含1.5 mM Ca2+和1.5 mM Mg2+的林格液冲洗1小时后重复实验。在用无Ca(2+)林格液灌注4小时后,喹哌嗪(一种5-羟色胺2A激动剂,100 microM)未诱导明显的轴突兴奋性变化(幅度变化为1.4 +/- 1.3%,用药前对照水平的百分比,+/-标准差,n = 6)。100 microM浓度的8-羟基-二丙基氨基四氢萘(一种5-羟色胺1A激动剂)使反应幅度降低36.3 +/- 4.2%(+/-标准差,P < 0.0005,n = 7),并使潜伏期延长22.3 +/- 4.3%(+/-标准差,P < 0.0005,n = 7)。应用5-羟色胺(100 microM)使幅度降低6.6 +/- 5.0%(+/-标准差,P < 0.05,n = 6)。用离子选择性微电极在背柱的不同深度测量细胞外钙浓度([Ca2+]e)。用无Ca(2+)林格液灌注4小时使背柱中的[Ca2+]e降至小于0.1 mM。在含1.5 mM Ca2+的林格液中,喹哌嗪使幅度增加38.3 +/- 5.8%(P < 0.0005,n = 6)。同样,5-羟色胺使幅度增加13.8 +/- 4.9%(P < 0.005,n = 6)。然而,相比之下,8-羟基-二丙基氨基四氢萘仍使幅度降低35.0 +/- 6.4%(P < 0.0005,n = 7),并使潜伏期延长24.1 +/- 4.5%(P < 0.0005,n = 7)。在实验2中,我们研究了钙依赖性和cAMP介导的蛋白激酶信号通路,以评估它们作为5-羟色胺2A受体激活的细胞内信使的作用。两种蛋白激酶抑制剂,50 microM H7(蛋白激酶C和c-AMP依赖性蛋白激酶的抑制剂)和100 microM D-鞘氨醇(蛋白激酶A和C的抑制剂)有效地消除了5-羟色胺2A激动剂的兴奋作用。100 microM镉(一种Ca2+通道阻滞剂)也阻断了喹哌嗪的作用。这些蛋白激酶抑制剂单独使用或镉单独使用均不影响动作电位幅度。这些结果表明,用Mg2+替代Ca2+可阻断喹哌嗪的兴奋作用,但不阻止8-羟基-二丙基氨基四氢萘的抑制作用,并且钙介导的蛋白激酶机制调节5-羟色胺及其激动剂诱导的轴突兴奋性变化。